NKG2A参与抗肿瘤免疫的生物学机制及前景
Biological mechanism and prospect of NKG2A in anti-tumor immunity
袁航 1郭朗睿 2谢芳1
作者信息
- 1. 苏州大学基础医学与生物科学学院 病理学与病理生理学系,苏州 215123
- 2. 苏州大学社会学院 档案与电子政务系,苏州 215000
- 折叠
摘要
自然杀伤细胞受体第二组成员A(natural killer cell receptor group Ⅱ number A,NKG2A)是NKG2受体家族的抑制性受体成员,主要表达在以NK细胞为代表的多种免疫细胞上,研究发现NKG2A参与多种肿瘤的发生、发展.目前针对NKG2A的靶向药物已进入一系列上皮性肿瘤的临床期试验.该文通过阐述NKG2A的生物学特性及其在CD8+T细胞、NK细胞等免疫细胞中的生物学作用,进而探讨NKG2A作为免疫检查点在抗肿瘤免疫中的作用机制,以期为临床抗肿瘤免疫治疗提供理论依据.
Abstract
Natural killer cell receptor group Ⅱ member A(NKG2A)is an inhibitory receptor of the NKG2 receptor family,which is mainly expressed on a variety of immune cells represented by NK cells.Studies have also revealed that NKG2A is involved in the development of a variety of tumors.NKG2A targeting drugs are currently in clinical phase trials for multiple epithelial tumors.The review describes the biological properties of NKG2A and its regulatory role on CD8+T cells,NK cells,and other immune cells.The review further explores the mechanism of NKG2A as an immune checkpoint in anti-tumor immu-nity,and provides a theoretical basis for clinical anti-tumor immunotherapy.
关键词
CD94/自然杀伤细胞受体第二组成员A/人类白细胞抗原E/CD8+T细胞/自然杀伤细胞/肿瘤免疫Key words
CD94/natural killer cell receptor group Ⅱ member A/human leukocyte antigen E/CD8+T cell/natural killer cell/tumor immunity引用本文复制引用
基金项目
国家自然科学基金(82073374)
国家自然科学基金(81772809)
出版年
2024
NETL
NSTL
万方数据